Ratings by Leerink (Asthika Goonewardene)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/5/2026 | Zentalis Pharmaceuticals | ZNTL | New Coverage | Outperform (N/A) |
2.52 (2.41) |
-4.37% | Details | |
| 10/5/2026 | Exelixis | EXEL | New Coverage | Market Perform (N/A) |
58.39 (65.31) |
11.85% | Details | |
| 10/5/2026 | Genmab A/S | GMAB | New Coverage | Outperform (N/A) |
34.75 (40.00) |
15.11% | Details | |
| 10/5/2026 | ORIC Pharmaceuticals | ORIC | New Coverage | Outperform (N/A) |
12.21 (13.63) |
11.63% | Details | |
| 7/21/2026 | Whitehawk Therapeutics | WHWK | New Coverage | Outperform (N/A) |
3.79 (3.25) |
-14.25% | Details | |
| 7/21/2026 | Molecular Partners | MOLN | New Coverage | Outperform (N/A) |
4.00 (3.61) |
-9.75% | Details | |
| 7/21/2026 | Kura Oncology | KURA | New Coverage | Outperform (N/A) |
10.68 (9.86) |
-7.68% | Details | |
| 7/21/2026 | Compass Therapeutics | CMPX | New Coverage | Outperform (N/A) |
2.02 (0.80) |
-60.4% | Details | |
| 7/21/2026 | Aktis Oncology | AKTS | New Coverage | Outperform (N/A) |
23.96 (16.76) |
-30.05% | Details |
